Apellis Pharmaceuticals Stock Current Valuation
| APLS Stock | USD 24.14 0.01 0.04% |
Valuation analysis of Apellis Pharmaceuticals helps investors to measure Apellis Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Apellis Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Apellis Pharmaceuticals is based on 3 months time horizon. Increasing Apellis Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Apellis stock is determined by what a typical buyer is willing to pay for full or partial control of Apellis Pharmaceuticals. Since Apellis Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Apellis Stock. However, Apellis Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.14 | Real 22.46 | Hype 24.14 | Naive 25.11 |
The intrinsic value of Apellis Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Apellis Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Apellis Pharmaceuticals helps investors to forecast how Apellis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Apellis Pharmaceuticals more accurately as focusing exclusively on Apellis Pharmaceuticals' fundamentals will not take into account other important factors: Apellis Pharmaceuticals Company Current Valuation Analysis
Apellis Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Apellis Pharmaceuticals Current Valuation | 3.09 B |
Most of Apellis Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apellis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Apellis Pharmaceuticals has a Current Valuation of 3.09 B. This is 78.49% lower than that of the Biotechnology sector and 33.49% lower than that of the Health Care industry. The current valuation for all United States stocks is 81.41% higher than that of the company.
Apellis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apellis Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics of similar companies.Apellis Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Apellis Fundamentals
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 3.09 B | ||||
| Shares Outstanding | 125.52 M | ||||
| Shares Owned By Insiders | 13.85 % | ||||
| Shares Owned By Institutions | 86.15 % | ||||
| Number Of Shares Shorted | 17.34 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 13.26 X | ||||
| Price To Sales | 3.88 X | ||||
| Revenue | 709.95 M | ||||
| Gross Profit | 336.07 M | ||||
| EBITDA | (236.39 M) | ||||
| Net Income | (197.88 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 469.78 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 1.84 X | ||||
| Cash Flow From Operations | (87.87 M) | ||||
| Short Ratio | 13.02 X | ||||
| Earnings Per Share | (1.60) X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 43.15 | ||||
| Number Of Employees | 705 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 3.03 B | ||||
| Total Asset | 885.05 M | ||||
| Retained Earnings | (3.04 B) | ||||
| Working Capital | 603.45 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 885.05 M |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.